Efficacy of trimethoprim–sulfamethoxazole in combination with an echinocandin as a first-line treatment option for Pneumocystis pneumonia: a systematic review and …
H Kato, M Hagihara, N Asai, T Umemura, Y Shibata… - Antibiotics, 2022 - mdpi.com
Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus
echinocandins has been reported to reduce the mortality of patients with pneumocystis …
echinocandins has been reported to reduce the mortality of patients with pneumocystis …
The effectiveness and safety of low dose trimethoprim‐sulfamethoxazole for the treatment of pneumocystis pneumonia: a systematic review and meta‐analysis
BJ Tritle, AA Hejazi, TT Timbrook - Transplant Infectious …, 2021 - Wiley Online Library
Background Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection
causing significant morbidity and mortality in immunocompromised patients. The …
causing significant morbidity and mortality in immunocompromised patients. The …
Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort …
D Creemers-Schild, FP Kroon, EJ Kuijper, MGJ de Boer - Infection, 2016 - Springer
Background The recommended treatment of Pneumocystis jirovecii pneumonia (PCP) is
high-dose trimethoprim–sulfamethoxazole (TMP–SMX) in an equivalent of TMP 15–20 …
high-dose trimethoprim–sulfamethoxazole (TMP–SMX) in an equivalent of TMP 15–20 …
Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first‑line therapy to treat non‑HIV patients with severe pneumocystis pneumonia
G Zhang, M Chen, S Zhang… - Experimental and …, 2018 - spandidos-publications.com
Combined treatment with caspofungin and trimethoprim/sulfamethoxazole (TMP/SMZ) as
salvage therapy in non‑HIV positive patients with severe pneumocystis pneumonia (PCP) …
salvage therapy in non‑HIV positive patients with severe pneumocystis pneumonia (PCP) …
A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis pneumonia in patients …
M Kosaka, A Ushiki, Y Ikuyama, K Hirai… - Antimicrobial agents …, 2017 - Am Soc Microbiol
The dose of trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of Pneumocystis
pneumonia (PCP) in patients without human immunodeficiency virus (HIV) infection has not …
pneumonia (PCP) in patients without human immunodeficiency virus (HIV) infection has not …
[HTML][HTML] Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised …
K Nakashima, M Aoshima, T Nakashita, M Hara… - Journal of Microbiology …, 2018 - Elsevier
Abstract Background/Purpose The efficacy of low-dose trimethoprim-sulfamethoxazole (TMP-
SMX) may be acceptable for the treatment of pneumocystis pneumonia (PCP) in non-human …
SMX) may be acceptable for the treatment of pneumocystis pneumonia (PCP) in non-human …
Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis
G Butler-Laporte, E Smyth, A Amar-Zifkin… - Open forum …, 2020 - academic.oup.com
Background Pneumocystis jirovecii pneumonia (PJP) remains a common and highly morbid
infection for immunocompromised patients. Trimethoprim-sulfamethoxazole (TMP-SMX) is …
infection for immunocompromised patients. Trimethoprim-sulfamethoxazole (TMP-SMX) is …
Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled …
ZN Sohani, G Butler-Laporte, A Aw, S Belga… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection of
immunocompromised hosts with significant morbidity and mortality. The current standard of …
immunocompromised hosts with significant morbidity and mortality. The current standard of …
Low-dose vs conventional-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in patients not infected with HIV: a multicenter, retrospective …
T Nagai, H Matsui, H Fujioka, Y Homma, A Otsuki, H Ito… - Chest, 2024 - Elsevier
Background Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective treatment for
Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without …
Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without …
Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole
Evidence supporting the use of an echinocandin alone as an alternative agent for the
treatment of Pneumocystis jirovecii pneumonia (PCP) is limited and controversial. This …
treatment of Pneumocystis jirovecii pneumonia (PCP) is limited and controversial. This …
相关搜索
- pneumocystis pneumonia trimethoprim sulfamethoxazole
- pneumocystis pneumonia meta analysis
- pneumocystis pneumonia low dose
- low dose trimethoprim sulfamethoxazole
- pneumocystis pneumonia combination with an echinocandin
- treatment option sulfamethoxazole in combination
- meta analysis sulfamethoxazole in combination
- meta analysis treatment option
- pneumocystis pneumonia treatment option
- efficacy of trimethoprim sulfamethoxazole in combination
- treatment option efficacy of trimethoprim
- meta analysis efficacy of trimethoprim
- pneumocystis pneumonia efficacy of caspofungin
- treatment of pneumocystis low tmp
- meta analysis tmp smx
- pneumocystis pneumonia immunocompromised patients